Biotech | June 01, 2022
Novavax initiates phase 3 trial of its COVID-19 omicron booster
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection
City of Hope is first in world to test oncolytic virus, CF33-hNIS, in people with metastatic solid tumours
Children 5 through 11 years of age are now authorized to receive a booster dose at least five months after the second dose of the two-dose primary series
The plan is to advance innovative therapies to drug-resistant cancers
Under the 5-year exclusive agreement, Artemis DNA will provide Datar's pioneering cancer detection Liquid Biopsies in the USA and Vietnam markets
Aims to increase compliance and improve outcomes for People with Diabetes (PwD)
Subscribe To Our Newsletter & Stay Updated
